Therefore, the 2019 American Diabetes Association (ADA) guidelines strongly recommend that SGLT2 inhibitors should be added to their prescriptions for T2DM patients with CKD or heart failure (Buse et al., 2020). Here, SLC5A2 is linked to diabetes mellitus.